NASDAQ:TBIO Telesis Bio (TBIO) Stock Price, News & Analysis $0.53 -0.02 (-3.64%) As of 11:58 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainSEC FilingsTrendsBuy This Stock About Telesis Bio Stock (NASDAQ:TBIO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Telesis Bio alerts:Sign Up Key Stats Today's Range$0.40▼$0.5350-Day Range$0.28▼$1.1052-Week Range$0.25▼$7.29Volume412 shsAverage Volume7,162 shsMarket Capitalization$954,879.80P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTelesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.Read More… Receive TBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telesis Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TBIO Stock News HeadlinesTelesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA SynthesisMarch 20, 2025 | finance.yahoo.comTelesis Bio Announces Departure of Chief Legal OfficerOctober 25, 2024 | markets.businessinsider.comVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.May 1, 2025 | Stansberry Research (Ad)Telesis Bio Shares Double After News of Beckman Coulter Life Sciences CollaborationSeptember 27, 2024 | marketwatch.comWhat's Going On With Telesis Bio Shares Thursday?September 27, 2024 | msn.comTelesis Bio Stock Is Soaring Wednesday: What's Going On?September 26, 2024 | msn.comTelesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA SynthesisSeptember 25, 2024 | globenewswire.comTelesis Bio Plans to Delist its Securities from The Nasdaq Stock MarketSeptember 10, 2024 | globenewswire.comSee More Headlines TBIO Stock Analysis - Frequently Asked Questions How have TBIO shares performed this year? Telesis Bio's stock was trading at $0.40 at the beginning of 2025. Since then, TBIO stock has increased by 32.5% and is now trading at $0.5299. View the best growth stocks for 2025 here. How were Telesis Bio's earnings last quarter? Telesis Bio, Inc. (NASDAQ:TBIO) announced its quarterly earnings data on Monday, November, 8th. The company reported ($6.12) earnings per share for the quarter, missing analysts' consensus estimates of ($5.04) by $1.08. The firm had revenue of $2.79 million for the quarter, compared to the consensus estimate of $2.93 million. When did Telesis Bio's stock split? Shares of Telesis Bio reverse split on Thursday, May 9th 2024. The 1-18 reverse split was announced on Thursday, May 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Telesis Bio IPO? Telesis Bio (TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at a price of $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. How do I buy shares of Telesis Bio? Shares of TBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Telesis Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Telesis Bio investors own include Ford Motor (F), Pfizer (PFE), PayPal (PYPL), SoFi Technologies (SOFI), Plug Power (PLUG) and XPeng (XPEV). Company Calendar Last Earnings11/08/2021Today5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TBIO Previous SymbolNASDAQ:DNAY CIK1850079 Webtelesisbio.com Phone858-228-4115FaxN/AEmployees200Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($28.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,720,000.00 Net Margins-336.59% Pretax Margin-334.81% Return on EquityN/A Return on Assets-61.89% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.06 Sales & Book Value Annual Sales$225.09 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.14 per share Price / Book3.93Miscellaneous Outstanding Shares1,802,000Free Float1,360,000Market Cap$990,919.80 OptionableOptionable Beta1.57 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:TBIO) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telesis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telesis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.